Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhofanib in biologic-refractory ulcerative colitis
IRCT20181217042020N3Phase 2Completed
- Sponsor
- Digestive Disease Research Institute
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tofacitinib in autoimmune colitis, sponsored by Digestive Disease Research Institute. Primary endpoint: Severity of disease. Started Sep 2022; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on IRCT20181217042020N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20181217042020N3.